Advancing Drug Delivery Technologies
  • About IMU
    • Corporate Profile
    • Our Vision & Mission
    • Our People
  • Linguet
    • Market Opportunities
    • Vitamin D
    • Pain Relief (NSAIDs)
    • Parkinsons Disease
    • Intellectual Property
  • Investor Centre
    • Analyst Coverage
    • Annual Reports
    • ASX Announcements
    • Investor Presentations
    • Media Coverage
    • Newsletters
  • Contact Us
Picture
Picture
Picture

Welcome to IMUGENE

Imugene Limited is an Australian based pharmaceutical company with a drug delivery platform at the centre of its assets.  It uses its proprietary drug delivery technology to improve the efficacy and safety of a diverse number of existing prescription and over the counter medicines. Its platform technology, known as Linguet™, enables the active ingredient of drugs to be absorbed straight into the bloodstream when placed inside the cheek (via the buccal mucosa) or under the tongue (sublingual).
How does Linguet differ from other buccal or sublingual delivery platforms?
There are two key differentiators for the Linguet intellectual property and proprietary know-how.   The first is that Linguet is manufactured using traditional dry tableting processes making it feasible and cost efficient to manufacture.

The second is that Linguet allows for drug formulation where slight modifications to the ratio of PEG's* produce Linguet's having different dissolution rates allowing flexibility of mucosal penetration when incorporating different active pharmaceutical drugs.
Linguet™ drug delivery technology helps protect small molecule drugs in oral delivery, including enhanced absorption across the oral membranes or by swallowing:
  1. Up to 68% of the general population in the UK suffers from difficulty in swallowing tablets**.
  2. Oral medicine is the largest segment of pharmaceuticals, yet there are few solutions for the Dysphagia (swallowing problems) market.   Linguet offers opportunities to address the issues of Dysphagia.
 
              *    PEG's are short for polyethylene glycol's with different lengths. 
              PEG's are known to enhance the transport of drugs across mucosal membranes.
              ** Strachan I and Greener M Pharmacy in Practice 2005;15: 411–414
Picture
Dysphagia is the medical term for the symptom of difficulty in swallowing. According to the Canadian Association of Speech-Language Pathologists and Audiologists, "We swallow on the average, about 600 times a day. It's estimated that about one in 10 people over 50 have some type of swallowing disorder".

LATEST NEWS &
MEDIA UPDATES

14/05/2013 - Merger Markets
01/05/2013 - Fierce Drug Delivery






RECENT ASX ANNOUNCEMENTS

23/05/2013 - IMU Progresses Vit D Dev Program
01/05 2013 - IMU Release Investor Presentation

30/04/2013 - Share Purchase Plan





2011/12 Annual report

Picture

Picture


About IMU
Corporate Profile
Our Vision & Mission
Our People


Linguet
Market Opportunities
 Vitamin D
Pain Relief (NSAIDs)
Parkinson's Disease

Analyst Coverage
Annual Reports
ASX Announcements
Investor Presentations
Media Coverage
Newsletters

Blog
Contact IMU
t: 03 9824 5254      f: 03 8080 0796
Suite 1, 1233 High Street, Armadale 3143
© 2013 Imugene Ltd. All rights reserved.  ABN 99 009 179 551                                                       Share Trading Policy | Privacy Policy I Forward Looking Statement
Website by Spiced Communications & Design